New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2021, including: Aprea, Redx, Syros.

New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2021, including: Astellas, Astrazeneca, Beyondspring, Byondis, Carsgen, Cstone, Daiichi, Exelixis, Genentech, Genmab, GT, Innovent, Immunocore, Ipsen, Janssen, Merck, Mirati, Novartis, Ose, Regeneron, Sanofi, Spectrum, Verastem, Veru.

Despite Beyondspring Pharmaceuticals Inc.’s phase III study meeting its primary and key secondary endpoints of a plinabulin/docetaxel combination in treating non-small-cell lung cancer (NSCLC), the company stock (NADAQ:BYSI) took a pounding. Shares sunk 32.9% on Sept. 20 to close at $15.36 each.